What is ImpriMed?
Founded in 2017 and headquartered in Palo Alto, California, ImpriMed is at the forefront of veterinary diagnostics, specializing in the analysis of live cancer cells from pet patients. The company's proprietary technology allows for the collection and interpretation of critical systemic information, aiming to provide more precise and effective cancer treatment strategies for animals. This focus on direct cellular analysis positions ImpriMed as a key player in advancing personalized medicine within veterinary oncology, addressing a growing need for sophisticated diagnostic tools in pet healthcare.
How much funding has ImpriMed raised?
ImpriMed has raised a total of $31M across 2 funding rounds:
Other Financing Round
$8M
Series A
$23M
Other Financing Round (2021): $8M with participation from Primer Sazze Partners, Murex Partners, E.S. Investments, HG Initiative, Draper Dragon, Draper Associates, Futureplay, BonAngels, and Translink Investment
Series A (2023): $23M led by Samyang Chemical Group (삼양화학그룹, SK Telecom, Byucksan, and Murex Partners
Key Investors in ImpriMed
Draper Dragon
Draper Dragon is a cross-border venture fund founded in 2006 that connects Silicon Valley and Asia, focusing on early-stage companies in the blockchain and Web3 sectors. The firm partners with visionary founders to drive innovative solutions and has a global presence with offices in major cities including Silicon Valley, Toronto, and Shanghai. As a core member of the Draper Venture Network, Draper Dragon leverages two decades of venture capital experience to empower startups that are redefining global industries. Their portfolio includes notable investments in companies like Coinbase, Ledger, and Otter AI.
Draper Associates
Draper Fisher Jurvetson is a leading venture capital firm with a global presence through a network of affiliated funds, with offices in more than 30 cities around the world and approximately $6 Billion in capital commitments. DFJ's mission is to identify, serve and provide capital for extraordinary entrepreneurs anywhere who are determined to change the world. Over the past twenty years, DFJ has been proud to back over 500 companies across many sectors including such industry changing catalysts as Hotmail (acquired by MSFT), Baidu (BIDU), Skype (acquired by EBAY), EnerNOC (ENOC), athenahealth (ATHN), Focus Media (FMCN), Mobile 365 (acquired by Sybase), xFire (acquired by Viacom), United Online (UNTD), Overture (acquired by YHOO), Interwoven (IWOV), Four11 (acquired by YHOO), Massive (acquired by MSFT), Parametric (PMTC) and Mozy (acquired by EMC).
Samyang Chemical Group (삼양화학그룹
Samyang Chemical Group focuses on various core businesses including chemicals, distribution, steel, real estate, and IT. The company is also engaged in new business development and investment in promising startups through its initiative, DREAUM. With a commitment to innovation and progress, they aim to transform possibilities into reality. Their target clients span across multiple sectors, benefiting from their comprehensive range of services.
What's next for ImpriMed?
The recent major strategic investment signals ImpriMed's transition into a scaling phase, likely enabling the company to expand its operational capacity, further develop its technology platform, and broaden its market reach. With substantial backing, ImpriMed is poised to enhance its research and development efforts, potentially exploring new applications for its diagnostic capabilities and solidifying its position as a leader in pet cancer care. The company's trajectory suggests a strategic focus on leveraging this capital to drive innovation and capture a larger share of the rapidly evolving veterinary diagnostics market.
See full ImpriMed company page
